Evidence map›Paper›PMID 18570588›Full record

ArticleViral immunology2008

Disruption of IFN-gamma- mediated antiviral activity in neurons: the role of cannabinoids.

R Antonio Herrera, Joseph H Oved, Carol Shoshkes Reiss

Open access · greenAbstract read
In one paragraph

Article in Viral immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Cannabinoids and Viral Infections.Pharmaceuticals (Basel, Switzerland) · 2010
    Article
  4. DISTINCT MECHANISMS OF INHIBITION OF VSV REPLICATION IN NEURONS MEDIATED BY TYPE I AND TYPE II IFN.Virus reviews & research : journal of the Brazilian Society for Virology · 2009
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

R Antonio HerreraDepartment of Biology, New York University, New York, New York, USA.
Joseph H Oved
Carol Shoshkes Reiss
New York University · USIcahn School of Medicine at Mount Sinai · US

Funding

IL 12 ACTIVATION OF NEURONSR01NS039746 · NINDS · NEW YORK UNIVERSITY · PI REISS, CAROL SHOSHKES · 2000 to 2009
$2.9M
VSV INFECTION OF THE CNS--MECHANISMS OF IL 12R01DC003536 · NIDCD · NEW YORK UNIVERSITY · PI REISS, CAROL SHOSHKES · 1997 to 2005
$1.3M
NIDCD NIH HHS R01 DC003536NINDS NIH HHS R01 NS039746
6 · The paper itself

Abstract

Interferon-gamma (IFN-gamma) has potent antiviral activity in neurons which is affected by the production of nitric oxide (NO). This study examines the interactions between cannabinoid receptor-1 (CB(1)), IFNgamma-induced pathways, and inhibition of vesicular stomatitis virus (VSV) replication in neuronal cells. CB(1) is abundantly expressed in neurons of the CNS and the NB41A3 neuroblastoma cell line. CB(1) activation of NB41A3 cells by the synthetic cannabinoid, WIN55,212-2, is associated with an inhibition of Ca(2+) mobilization, leading to diminished nitric oxide synthase (NOS)-1 activity and the production of NO, in vitro. This ultimately results in antagonism of IFN-gamma-mediated antiviral activity and enhanced viral replication. Therefore, activation of cells expressing CB(1) by endogenous (or exogenous) ligands may contribute to decreased inflammation and to increased viral replication in neurons and disease in the CNS.

Indexed as

AnimalsCannabinoidsCell LineCell SurvivalHumansImmunologic FactorsInterferon-gammaMiceNeuronsNitric OxideReceptors, CannabinoidVesicular stomatitis Indiana virusViral Plaque AssayVirus ReplicationCannabinoidsImmunologic FactorsInterferon-gammaNitric OxideReceptors, Cannabinoid

Identifiers

PMID18570588
PMCPMC2556635
OpenAlexW2026130103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.